The European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have collaborated on the Innovative Medicines Initiative (IMI), which has announced the commencement of the public-private research programme OPTIMA which is defined as Optimal Treatment for Patients & Solid Tumours in Europe Through Artificial Intelligence.
The €21.3 million programme aims to employ AI to enhance treatment for individuals with lung, breast, and prostate cancer. The objective of OPTIMA is to design, create, and deliver the first interoperable, GDPR-compliant real-world oncology information and proof-generating platform in Europe, allowing medical practitioners to offer each patient with solid tumours from the three malignancies the best possible individualised care.
AstraZeneca and MUTABOR are now formally partners in the research, thirteen months after it began. The project’s coordinators, Professor Dr. James N’Dow of the University of Aberdeen’s Academic Urology Unit and the European Association of Urology, and Dr. Hagen Krüger, senior medical director of oncology for Pfizer Germany, are happy that AstraZeneca and MUTABOR are now part of the project consortium. This means that the consortium’s knowledge will grow.
In order to ensure that the initiative is at the forefront of pushing the creation and deployment of individualised patient-centric oncological treatment for prostate, breast, and lung cancer across Europe, Professor N’Dow said that OPTIMA would work with AstraZeneca and MUTABOR.
OPTIMA has accumulated all the resources and knowledge needed to accomplish this; it is now time for them to work jointly in a highly collaborative environment to realise the lofty goals.Â
Oncology is one of the diseases for which AstraZeneca will concentrate on the research, development, and commercialization of prescription medications. Additionally, the business will test the data management with various user types and collect suggestions for modifications to help grow the platform.
David Dellamonica, who is in charge of digital and innovation for AstraZeneca’s cancer business in Europe and Canada, released a statement expressing the company’s pleasure upon learning that it has been accepted into the OPTIMA collaboration. Collecting information on actual cancer patients from all around Europe and, more significantly, making use of that knowledge is essential to achieving their common objective of transforming cancer treatment in Europe.
They will boost collaborative decision-making and build standardised, proofed treatment protocols by utilising the latest technologies to acquire practical insights from this large quantity of data. According to what he had previously stated, their ultimate objective is to expand the number of cancer patients who have access to the most recent developments in medical and scientific treatment.
